Growth-regulated Oncogene-α and Other Inflammatory Chemokines Expression in Follicular Fluid Cells in Patients with Polycystic Ovary Syndrome_West China Medical Journal

Authors：

 QINLang ,  LIXiao-hong , LUOShan , WANGYan , LIShang-wei , YANGYe-zhou

The Reproductive Center, Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University, Chengdu, Sichuan 610041, P. R. China;

Corresponding?author：

LIXiao-hong, Email: lixiaohongham_001@163.com

Keywords：

Polycystic ovary syndrome; Granulocyte; Growth-regulated oncogene-α; Chronic inflammatory

DOI：

10.7507/1002-0179.20150255

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To quantify cytokine and chemokine mRNA expression in follicular fluid cells obtained at the time of oocyte retrieval before IVF in women with and without polycystic ovary syndrome (PCOS). Methods Between January and August 2014, 80 subjects undergoing IVF-ET were chosen to be studied. Among them, 40 had PCOS, and the other 40 were controls. Follicular fluid cells were subjected to quantitative RT-PCR to evaluate growth-regulated oncogene-α (GRO-α), tumor necrosis factor-α (TNF-α), interleukins (IL-6, IL-8) expression relative to β-actin. And the chemokine was measured in serum and follicular fluids by immunoassays. These mRNA transcriptions production was proved by sequencing. Results GRO-α, TNF-α, IL-6 and IL-8 mRNA were expressed in follicular fluid cells. Their expressions were significantly higher in PCOS compared with controls (P<0.05). They were also detected higher in PCOS than controls in serum and follicular (P<0.05), but the difference of IL-6 level between PCOS and controls in lean patients was not statistically significant (P>0.05). Conclusion GRO-α, IL-8, TNF-α, and IL-6 may play important roles in the occurrence and development of PCOS. PCOS may be a chronic immunological inflammatory disease.

Citation： QINLang, LIXiao-hong, LUOShan, WANGYan, LIShang-wei, YANGYe-zhou. Growth-regulated Oncogene-α and Other Inflammatory Chemokines Expression in Follicular Fluid Cells in Patients with Polycystic Ovary Syndrome. West China Medical Journal, 2015, 30(5): 890-894. doi: 10.7507/1002-0179.20150255 Copy

1.	Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome:the complete task force report[J]. Fertil Steril, 2009, 91(2):456-488.
2.	González F. Inflammation in polycystic ovary syndrome:underpinning of insulin resistance and ovarian dysfunction[J]. Steroids, 2012, 77(4):300-305.
3.	Kelly CC, Lyall H, Petrie JR, et al. Low grade chronic inflammation in women with polycystic ovarian syndrome[J]. J Clin Endocrinol Metab, 2001, 86(6):2453-2455.
4.	M?hlig M, Spranger J, Osterhoff M, et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation[J]. Eur J Endocrinol, 2004, 150(4):525-532.
5.	Rajagopalan L, Rajarathnam K, et al. Ligand selectivity and affinity of chemokine receptor CXCR1. Role of N-terminal domain[J]. J Biol Chem, 2004, 279(29):30000-30008.
6.	Moser B, Clark-Lewis I, Zwahlen R, et al. Neutrophil-activating properties of the melanoma growth-stimulatory activity[J]. J Exp Med, 1990, 171(5):1797-1802.
7.	Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome[J]. Fertil Steril, 2004, 81(1):19-25.
8.	Sachse F, Von Eiff C, Becker K, et al. Proinflammatory impact of Staphylococcus epidermidis on the nasal epithelium quantified by IL-8 and GRO-alpha responses in primary human nasal epithelial cells[J]. Int Arch Allergy Immunol, 2008, 145(1):24-32.
9.	Klein AM, Anderson K, Lafreniere D, et al. Growth-related oncogene-alpha expression in human nasal polyps[J]. Otolaryngol Head Neck Surg, 2000, 123(1Pt1):85-90.
10.	Lim SS, Norman RJ, Davies MJ, et al. The effect of obesity on polycystic ovary syndrome:a systematic review and meta-analysis[J]. Obes Rev, 2013, 14(2):95-109.
11.	Xiong YL, Liang XY, Yang X, et al. Low-grade chronic inflammation in the peripheral blood and ovaries of women with polycystic ovarian syndrome[J]. Eur J Obstet Gynecol Reprod Biol, 2011, 159(1):148-150.
12.	Deligeoroglou E, Vrachnis N, Athanasopoulos N, et al. Mediators of chronic inflammation in polycystic ovarian syndrome[J]. Gynecol Endocrinol, 2012, 28(12):974-978.
13.	Boulman N, Levy Y, Leiba R, et al. Increased C-reactive protein levels in the polycystic ovary syndrome:a marker of cardiovascular disease[J]. J Clin Endocrinol Metab, 2004, 89(5):2160-2165.
14.	Velija-Asimi Z. C-reactive protein in obese PCOS women and the effect of metformin therapy[J]. Bosn J Basic Med Sci, 2007, 7(1):90-93.
15.	楊艷, 喬杰, 李美芝. 白細胞介素18、白細胞介素1β與多囊卵巢綜合征發病的相關性研究[J]. 中國實用婦科與產科雜志, 2008, 1(1):38-40.
16.	Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome[J]. Mol Cell Endocrinol, 2011, 335(1):30-41.
17.	Haghnegahdar H, Du J, Wang D, et al. The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma[J]. J Leukoc Biol. 2000, 67(1):53-62.
18.	Devalaraja RM, Nanney LB, Du J, et al. Delayed wound healing in CXCR2 knockout mice[J]. J Investig Dermato, 2000, 115(2):234-244.
19.	González F, Rote NS, Minium J, et al. In vitro evidence that hyperglycemia stimulates tumor necrosis factor-alpha release in obese women with polycystic ovary syndrome[J]. J Endocrinol, 2006, 188(3):521-529.
20.	Vgontzas AN, Trakada G, Bixler EO, et al. Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea[J]. Metabolism, 2006, 55(8):1076-1082.
21.	Amato G, Conte M, Mazziotti G, et al. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles[J]. Obstet Gynecol, 2003, 101(6):1177-1182.
22.	Walch K, Grimm C, Zeillinger P, et al. A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndrome[J]. Fertil Steril, 2004, 81(6):1638-1641.
23.	Benson S, Janssen OE, Hahn S, et al. Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome[J]. Brain Behav Immun, 2008, 22(2):177-184.
24.	Puder JJ, Varga S, Kraenzlin M, et al. Central fat excess in polycystic ovary syndrome:relation to low-grade inflammation and insulin resistance[J]. J Clin Endocrinol Metab, 2005, 90(11):6014-6021.
25.	Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome:the complete task force report[J]. Fertil Steril, 2009, 91(2):456-488.

1. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome:the complete task force report[J]. Fertil Steril, 2009, 91(2):456-488.
2. González F. Inflammation in polycystic ovary syndrome:underpinning of insulin resistance and ovarian dysfunction[J]. Steroids, 2012, 77(4):300-305.
3. Kelly CC, Lyall H, Petrie JR, et al. Low grade chronic inflammation in women with polycystic ovarian syndrome[J]. J Clin Endocrinol Metab, 2001, 86(6):2453-2455.
4. M?hlig M, Spranger J, Osterhoff M, et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation[J]. Eur J Endocrinol, 2004, 150(4):525-532.
5. Rajagopalan L, Rajarathnam K, et al. Ligand selectivity and affinity of chemokine receptor CXCR1. Role of N-terminal domain[J]. J Biol Chem, 2004, 279(29):30000-30008.
6. Moser B, Clark-Lewis I, Zwahlen R, et al. Neutrophil-activating properties of the melanoma growth-stimulatory activity[J]. J Exp Med, 1990, 171(5):1797-1802.
7. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome[J]. Fertil Steril, 2004, 81(1):19-25.
8. Sachse F, Von Eiff C, Becker K, et al. Proinflammatory impact of Staphylococcus epidermidis on the nasal epithelium quantified by IL-8 and GRO-alpha responses in primary human nasal epithelial cells[J]. Int Arch Allergy Immunol, 2008, 145(1):24-32.
9. Klein AM, Anderson K, Lafreniere D, et al. Growth-related oncogene-alpha expression in human nasal polyps[J]. Otolaryngol Head Neck Surg, 2000, 123(1Pt1):85-90.
10. Lim SS, Norman RJ, Davies MJ, et al. The effect of obesity on polycystic ovary syndrome:a systematic review and meta-analysis[J]. Obes Rev, 2013, 14(2):95-109.
11. Xiong YL, Liang XY, Yang X, et al. Low-grade chronic inflammation in the peripheral blood and ovaries of women with polycystic ovarian syndrome[J]. Eur J Obstet Gynecol Reprod Biol, 2011, 159(1):148-150.
12. Deligeoroglou E, Vrachnis N, Athanasopoulos N, et al. Mediators of chronic inflammation in polycystic ovarian syndrome[J]. Gynecol Endocrinol, 2012, 28(12):974-978.
13. Boulman N, Levy Y, Leiba R, et al. Increased C-reactive protein levels in the polycystic ovary syndrome:a marker of cardiovascular disease[J]. J Clin Endocrinol Metab, 2004, 89(5):2160-2165.
14. Velija-Asimi Z. C-reactive protein in obese PCOS women and the effect of metformin therapy[J]. Bosn J Basic Med Sci, 2007, 7(1):90-93.
15. 楊艷, 喬杰, 李美芝. 白細胞介素18、白細胞介素1β與多囊卵巢綜合征發病的相關性研究[J]. 中國實用婦科與產科雜志, 2008, 1(1):38-40.
16. Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome[J]. Mol Cell Endocrinol, 2011, 335(1):30-41.
17. Haghnegahdar H, Du J, Wang D, et al. The tumorigenic and angiogenic effects of MGSA/GRO proteins in melanoma[J]. J Leukoc Biol. 2000, 67(1):53-62.
18. Devalaraja RM, Nanney LB, Du J, et al. Delayed wound healing in CXCR2 knockout mice[J]. J Investig Dermato, 2000, 115(2):234-244.
19. González F, Rote NS, Minium J, et al. In vitro evidence that hyperglycemia stimulates tumor necrosis factor-alpha release in obese women with polycystic ovary syndrome[J]. J Endocrinol, 2006, 188(3):521-529.
20. Vgontzas AN, Trakada G, Bixler EO, et al. Plasma interleukin 6 levels are elevated in polycystic ovary syndrome independently of obesity or sleep apnea[J]. Metabolism, 2006, 55(8):1076-1082.
21. Amato G, Conte M, Mazziotti G, et al. Serum and follicular fluid cytokines in polycystic ovary syndrome during stimulated cycles[J]. Obstet Gynecol, 2003, 101(6):1177-1182.
22. Walch K, Grimm C, Zeillinger P, et al. A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndrome[J]. Fertil Steril, 2004, 81(6):1638-1641.
23. Benson S, Janssen OE, Hahn S, et al. Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome[J]. Brain Behav Immun, 2008, 22(2):177-184.
24. Puder JJ, Varga S, Kraenzlin M, et al. Central fat excess in polycystic ovary syndrome:relation to low-grade inflammation and insulin resistance[J]. J Clin Endocrinol Metab, 2005, 90(11):6014-6021.
25. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome:the complete task force report[J]. Fertil Steril, 2009, 91(2):456-488.

Previous Article
Clinical Features and Outcomes of Relapsed Acute Lymphoblastic Leukemia in Children
Next Article
Comparison of Three Therapeutic Strategies for Cesarean Scar Pregnancy

West China Medical Journal

Growth-regulated Oncogene-α and Other Inflammatory Chemokines Expression in Follicular Fluid Cells in Patients with Polycystic Ovary Syndrome

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content